论文部分内容阅读
T细胞可以通过表达嵌合抗原受体(CAR)对肿瘤靶细胞进行识别和杀灭.CART细胞治疗在血液系统肿瘤中疗效显著,但是在实体瘤中疗效有限.然而CART细胞治疗也可引起预期或不能预期的不良反应,包括细胞因子释放综合征、神经系统毒性、脱靶效应和过敏反应.理论上的不良反应还包括克隆扩增继发插入癌变、移植物抗宿主病和靶抗原不能识别.减轻不良反应已成为这一新兴技术成功应用的关键.文章综述CART细胞治疗的不良反应,以及理论上存在的不良反应及应对策略.“,”T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated its clinical efficacy in hematologic malignancies with evident responses when targeting solid tumors. However, CAR T cells therapy also has the capacity to elicit expected and unexpected toxicities including cytokine release syndrome, neurologic toxicity, “on target/off tumor” recognition, and anaphylaxis. Theoretical toxicities include clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells therapy and strategies to cope with it.